Both in Pharmaceuticals
Relmada Therapeutics vs Phathom Pharmaceuticals
Over the past year RLMD returned +50.5% and PHAT returned −57.9%; their daily moves had a correlation of 0.21.
RLMD +50.5% PHAT −57.9%Growth of $1, one year, split-adjusted
| Metric | RLMD | PHAT |
|---|---|---|
| Price | $4.17 | $5.68 |
| Market cap | $444.8M | $461.7M |
| Today | −2.34% | −1.05% |
| 1 month | +27.1% | −16.2% |
| 6 months | −46.9% | −55.2% |
| Year to date | −13.7% | −65.8% |
| 1 year | +89.5% | −58.6% |
| Revenue growth (YoY) | — | +71.1% |
| Gross margin | — | 78.3% |
| Net margin | — | −16.4% |
| P/E (TTM) | — | — |
| Price / sales | — | 1.7× |
| Net cash | $217.7M | $17.6M |
| Dividend yield | — | — |
| Volatility (60d) | 60.0% | 72.0% |
| Short % of float | 14.0% | 17.5% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).